This work was carried out in collaboration between all authors.Author MEGF was the principal investigator, designed the study, conducted the data analysis and wrote of the paper. Author M-LDH oversaw the laboratory measurements and performed the statistical analysis. Authors HV, CM and RG were the study neurologists, oversaw patient care and assisted with interpreting the results, Author EN classify the participants for the group control. Authors LB and MR assisted with interpreting the results.All authors read and approved the final manuscript.

No abstract

No abstract

No abstract

We have now applied the enzyme immunoassay using anti-NGF monoclonal antibody (MAb) 27/21 and a blocking test validating the specificity of the immunoreactivity for NGF in serum samples to examine NGF levels in normal rat sera, hemiparkinsonian rat sera, normal monkey sera, and MPTP-treated monkey sera. The levels of NGF in treated animals showed reductions when compared with serum from normal animals. The NGF level alterations observed in lesioned animals and in human parkinsonian patients evidence a relationship between this neurotrophic factor and the neurodegenerative changes observed in Parkinson disease (PD).

No abstract

No abstract

No abstract